Project Grant HT94252510782
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$110K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Berkeley, CA 94702, USA
Similar Awards
The federal Project Grant award of $1,008,313 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. This award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The award was granted to The Regents of the University of California, San Francisco (UCSF), a prominent academic medical center and research institution, to conduct research on melanoma....
The federal Project Grant award, valued at $176,000.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Sloan-Kettering Institute for Cancer Research in establishing a mouse model of myxoid/round cell liposarcoma with endogenous translocations. This research aims to transform healthcare for military service members, veterans, and the broader public by advancing biomedical research on critical health...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development (CFDA 12.420) program, provides $2,985,093.00 to Plus Therapeutics, Inc. (Cytori) to develop a novel targeted radiotherapeutic for the treatment of pediatric high-grade glioma (HGG) and ependymoma. The award period runs from September 1, 2024 to August 31, 2027. The Military Medical Research and Development program supports advanced biomedical research aimed at transforming...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $660,000.00 in funding to Nucyrna Therapeutics Inc. in Framingham, MA to develop a SOD1-targeting iRNASO oligonucleotide drug candidate with improved efficacy and safety compared to tofersen. The award has a performance period from July 1, 2025 to June 30, 2027. The Military Medical Research and Development program supports advanced biomedical research...
The Defense Health Agency awarded a $682,049 Project Grant to The Washington University under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...
This federal Project Grant award of $400,000.00 was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, with a performance period from October 1, 2024 to September 30, 2026. The award supports research by the University of Maryland, Baltimore to develop "drug conjugates of modified LGR4/5/6 ligands for cancer treatment." The university, as the prime awardee, has extensive expertise in biomedical research, clinical trials, and...
The federal Project Grant award of $480,000.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development (CFDA 12.420) program supports research by Northwestern University to investigate the role of translation heterogeneity in ovarian cancer. The research aims to uncover insights that can transform healthcare for military service members, veterans, and the broader public. The project has a performance period from September 1, 2024 to August 31, 2026. This award is...
This Project Grant award, valued at $543,285.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the University of Washington will conduct research to develop new FDA-approved combination therapies for transforming the treatment of rhabdomyosarcoma, a rare...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,002,591.00 to Targepeutics, Inc. to determine the intratumoral drug distribution of the immunotoxin GB13 for the treatment of adult and pediatric brain cancers. The 3-year project aims to transform health care for Service Members and the American public through innovative and impactful biomedical research on medical solutions for the battlefield. The...
The Defense Health Agency awarded a $1,453,500.00 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, commencing on June 20, 2023, will support UCSF's research to profile and eliminate tumor subclones resistant to radioligand therapy. Through this project, UCSF aims to transform health care for Service Members and the American public by developing innovative and...